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A b s t r a c t
Background: Alcohol septal ablation (ASA) is an alternative to surgical treatment in patients with hypertrophic obstructive 
cardiomyopathy (HOCM). Through alcohol-induced necrosis, ASA leads to an increase in left ventricular outflow tract (LVOT) 
diameter and a decrease in LVOT pressure gradient. 
Aim: We sought to assess the effect of ASA on left ventricular (LV) wall thickness and mass, left atrial (LA) size, and N-terminal 
pro–B-type natriuretic peptide (NT-proBNP) level. 
Methods: The study cohort consisted of 50 patients with HOCM (30 in the ASA group, 20 in the optimal pharmacotherapy 
group [OPG]). Transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR), and NT-proBNP level analysis were 
performed at baseline and at six months. 
Results: All parameters are presented as means. In the ASA group, the maximal LVOT pressure gradient decreased from 122.7 to 
54.8 mmHg directly after ASA and to 37.2 mmHg after a further six months (p < 0.0001). The NT-proBNP level decreased from 
2174.4 to 1103.4 pg/mL (p < 0.001). On TTE, the interventricular septum (IVS) thickness decreased to from 23.6 to 19.4 mm 
(p < 0.0001) and the lateral wall (LW) thickness decreased from 15.9 to 14.2 mm (p < 0.007). On CMR, basal IVS thickness 
decreased from 23.7 to 18.0 mm (p < 0.0001) and the LW thickness decreased from 13.2 to 12.2 mm (p = 0.02). IVS mass 
reduced from 108.9 to 91.5 g (–16%; p < 0.001). All of the above parameters remained unchanged in the OPG.
Conclusions: Successful ASA reduces LV hypertrophy and improves parameters of the LV overload, resulting in LV wall hy-
pertrophy regression, and LA size and NT-proBNP level reduction. The above parameters may be as useful in assessing the 
efficacy of ASA as the LVOT gradient itself.
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INTRODUCTION
Alcohol septal ablation (ASA) was introduced two decades ago as 
a method of treatment for patients with hypertrophic obstructive 
cardiomyopathy (HOCM). Published data from high-volume 
centres confirmed its favourable short- and long-term clinical 
outcomes. ASA results in regression of the basal segment of the 
interventricular septum (IVS) as well as reduction of mitral leaflet 
systolic anterior movement (SAM) and mitral regurgitation (MR). 
In effect, it reduces left ventricular outflow tract (LVOT) gradient, 
leading to clinical improvement of HOCM symptoms [1–4].
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Typically, successful ASA leads to a gradual reduction of 
LVOT gradient. The reduction may continue for as long as 
six to 12 months after the procedure, as a consequence of 
post-infarct left ventricular (LV) remodelling [5–8].
Some data point out the fact that the N-terminal pro–
B-type natriuretic peptide (NT-proBNP) concentration in 
HOCM patients is elevated [9, 10]. The highest NT-proBNP 
levels are usually observed in patients with LVOT obstruc-
tion, LV diastolic dysfunction, and massive LV hypertrophy 
(LVH) [9, 11]. Type B natriuretic peptide is released mostly 
by cardiomyocytes of the left ventricle in response to stretch 
stimuli. The serum concentration of NT-proBNP is directly 
proportional to the LV filling pressure and is considered a sensi-
tive biochemical marker of LV dysfunction [12].
Until now few studies have evaluated the influence of 
ASA on the LV filling parameters [13, 14]. We attempted to 
reduce this gap by assessing the changes in left atrial (LA) size 
and NT-proBNP concentration, indirectly reflecting LV filling 
pressure, as well as LV mass changes.
METHODS
This was a single-centre, prospective, observational study 
including 50 patients recruited between December 2006 and 
August 2010. The study was performed at the Institute of 
Cardiology, Warsaw, Poland. 
The study group consisted of 30 consecutive HOCM 
patients (15 men) with a mean LVOT peak gradient of 
122.7 ± 32.8 mmHg, fulfilling the criteria for non-surgical 
ASA IVS gradient reduction. The final decision to perform 
ASA by injecting alcohol into the septal branch was made 
during an invasive diagnostic procedure directly preceding 
the injection, which involved several assessment modalities, 
including contrast echocardiography. The procedure was 
performed according to established standards [15]. Written, 
informed consent was obtained from all patients. 
The optimal pharmacotherapy group (OPG) consisted of 
20 patients (eight men) with a mean LVOT peak gradient of 
72.5 ± 29 mmHg, in whom ASA was not performed for the 
following reasons: lack of patient consent (six patients), thick-
ness of the basal septal segment < 18 mm (five patients), and 
unfavourable anatomy (lack of the septal branch or its location 
supplying the wrong area of the septum on echocardiographic 
contrast assessment, or a fistula from the septal branch to the 
right or left ventricle; nine patients). Because patients in the 
OPG were not candidates for surgical evaluation (myectomy), 
optimal pharmacotherapy was maintained.
All patients underwent transthoracic echocardiography (TTE) 
and had NT-proBNP serum levels assessed before and six months 
after the ASA procedure. In all eligible patients, cardiac magnetic 
resonance (CMR) was also performed. In OPG patients, blood 
samples were drawn at inclusion and at six months. In all cases, 
the samples were obtained after at least 30 min of bed rest.
The aims of the study were to confirm whether suc-
cessful gradient reduction in patients with HOCM improves 
selected parameters indirectly related to LV overload and to 
compare selected parameters between ASA-treated patients 
and the OPG. 
Ablation procedure
The technique of the ASA procedure has been described in 
our earlier papers [16, 17].
CMR methodology and data analysis
Cardiac magnetic resonance imaging was performed in the 
supine position, using a 1.5 T Siemens Avanto scanner (Sie-
mens, Erlangen, Germany). All examinations were done at 
the Institute of Cardiology, Warsaw, Poland.
Based on the preliminary views acquired using the 
black-blood spin echo sequences (half-Fournier acquisition 
single-shot turbo spin echo) in three planes — frontal, sagittal, 
and transverse — the long axis and the short axis of the heart 
were determined in each case.
Next, moving cinematic views were obtained using 
the steady-state free precession (SSFP) technique for the 
assessment of heart chamber dimensions and function. All 
acquisitions were electrocardiogram-gated. The two-chamber, 
three-chamber, and four-chamber long-axis views were 
recorded, as well as the serial short-axis views starting at 
the base of the heart and extending to the apex. The basic 
acquisition parameters of the balanced SSFP sequence were 
as follows: repetition time of 33–54 ms, echo time of 1.2 ms, 
flip angle of 64–79°, time resolution of 25 phases for each R-R 
interval, slice thickness of 8 mm, interslice interval of 1.6 mm, 
and field of view and matrix adjusted accordingly to suit the 
examination parameters.
All cinematographic acquisitions were analysed using 
the MASS software system (Medis, Leiden, Netherlands). 
This software allows for automatic delineation of endocar-
dial borders with papillary muscle exclusion and manual 
fine tuning as necessary in all acquired layers, in end-systole 
and end-diastole. Based on this, ejection fraction as well as 
end-diastolic and end-systolic volumes are calculated. Muscle 
mass may be calculated as well. Late gadolinium enhancement 
was defined as heart muscle area with signal intensity after 
contrast enhancement equal to half of the maximum muscle 
signal intensity registered (full length at half maximum).
All flow sequences were analysed using dedicated 
software (Argus, Siemens, Erlangen, Germany). The ex-
tent of MR was presented as the regurgitation fraction 
calculated using the following formula: (LVSV [mL] – aortic 
flow [mL]/LVSV [mL]) × 100%, where LVSV represents LV 
stroke volume.
Cardiac magnetic resonance imaging was performed 
before ASA and six months after the procedure.
Methodology of echocardiographic evaluation
Transthoracic echocardiography examinations were done 
at the Echocardiography Lab of the Institute of Cardiology 
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in Warsaw. M-mode, two-dimensional, and Doppler im-
ages were registered using Philips HD 15, GE Vivid 7, or GE 
Vivid I equipment (Philips, Amsterdam, Netherlands and 
GE, Boston, Massachusets, USA). Standard views, including 
parasternal long-axis view, short-axis view at the levels of the 
mitral valve, chords, and papillary muscles, as well as apical 
four-chamber and two-chamber views were acquired. LV 
end-systolic and end-diastolic diameters were assessed, and 
the LA and diastolic muscle thickness (IVS, lateral wall [LW], 
and anterior wall) were measured. Other parameters assessed 
included the level of outflow obstruction, LVOT gradient, the 
extent of MR, SAM, the extent of LVH (and whether the mid-
dle LV segment was significantly affected), and the presence 
of an intraventricular obstruction.
Transthoracic echocardiography examination was per-
formed at rest before, during, and two days after the ASA 
procedure. The examination was repeated before discharge, 
as well as at three- and six-month follow-up.
Statistical analysis
Continuous variables were presented as means ± standard 
deviation and categorical data as percentages. The sample 
size (n = 30) for the study group was calculated based on 
a = 0.05 and b = 0.8 and expected LVOT gradient reduction 
by 50% in TTE measurement. The study cohort consisted of 
50 patients: 20 in the OPG and 30 in the study group. 
All statistical analyses were done using the SAS 9.2 soft-
ware (SAS Institute, Cary, NC, USA). The significance of nor-
mally distributed data was assessed with the paired Student t 
test, while for non-normally distributed data, non-parametric 
rank and log-rank tests were used. The normality of distribution 
was evaluated using Shapiro-Wilk test. The relation of variables 
was assessed by Pearson’s correlation and linear regression in 
the case of normally distributed data. Non-parametric Spear-
man correlation was used for other variables. The significance of 
transformed categorical data was assessed using the McNamara 
test. The time point changes were evaluated using ANOVA for 
normally distributed variables and Wilcoxon’s test for other 
variables. The significance level for all data was set at p = 0.05.
RESULTS
The mean patient age at inclusion was 56.9 ± 11.9 years in the 
study group and 52.1 ± 18.8 years in the OPG (p = 0.13). All 
patients were treated with at least one drug (b-blocker: 36 patients; 
calcium channel blocker: 12 patients; b-blocker and amiodarone: 
five patients). Baseline characteristics of both groups were similar 
apart from the peak gradient assessed by TTE (Table 1).
Alcohol septal ablation procedure
During ASA the mean volume of absolute alcohol adminis-
tered into the first or second septal branch was 1.9 ± 0.5 mL. 
The creatine kinase-MB fraction (CK-MB) activity determined 
six and 12 h after ASA was 107 ± 55.9 U and 96.9 ± 49 U, re-
spectively, while troponin I (TnI) levels were 33 ± 32.8 ng/mL 
and 38.9 ± 37 ng/mL, respectively. 
The LVOT peak gradient, assessed by TTE, was 
reduced from 122.7 ± 32.8 mmHg at baseline, to 
54.8 ± 37 mmHg (p < 0.0001) immediately after the pro-
cedure, 51.8 ± 37 mmHg (p < 0.0001) at month three, and 
37.2 ± 27.8 mmHg (p < 0.0001) at month six. 
In the OPG, the peak LVOT gradient was 72.5 ± 
± 29 mmHg at baseline, 65.5 ± 28.6 mmHg at month three, 
and 65.3 ± 33 mmHg at six months (p = 0.44). 
Procedural success (peak LVOT gradient below 50 mmHg 
or a 50% reduction in peak LVOT gradient) at six-month 
follow-up was achieved in 26 out of 30 (87%) ASA pa-
tients. A meaningful improvement in clinical status expressed 
as New York Heart Association (NYHA) class was also noted. 
Before ASA three patients were in NYHA class II, eight patients 
were in NYHA class II/III, and 19 patients were in NYHA class 
III. At six-month follow-up, 19 patients were in NYHA class 
I or I/II, six patients were in NYHA class II, and six patients 
were in NYHA class II/III or III (Table 2).
There was no significant improvement in clinical status 
at six months in the OPG (Table 2).
Six months after the ASA procedure the NT-proBNP 
serum level decreased from 2174.4 ± 819.8 pg/mL to 
1103.4 ± 618 pg/mL (p < 0.0001) (Fig. 1). NT-proBNP 
remained unchanged in the OPG, the levels were 
2133.9 ± 1982.8 pg/mL and 2091.1 ± 1601.2 pg/mL 
(p = 0.18) at baseline and at six months, respectively (Table 2).
Echocardiographic evaluation
A trend toward a reduction in LA end-systolic diameter was 
observed in the group of ASA recipients (from 47.4 ± 6.4 mm 
before ASA to 45.2 ± 5.4 mm at month six; p = 0.06). 
A reduction in MR severity was also noted in this group. 
On TTE evaluation before ASA, mild MR was noted in nine 
patients, moderate MR in 17 patients, and significant MR in 
four patients. After six months, the respective numbers of 
patients were 24 (mild MR), four (moderate MR), and two 
(significant MR). IVS thickness decreased from 23.6 ± 3.5 mm 
at baseline to 19.3 ± 4 mm (p < 0.0001) and 19.4 ± 0.4 mm 
(p < 0.0001) at three- and six-month follow-up, respectively. 
Lateral wall thickness decreased from 15.9 ± 3.2 mm to 
14.9 ± 2.9 (p = 0.046) and 14.2 ± 2 (p = 0.007) at the 
same time points (Table 3).
In the OPG, all of the above TTE parameters remained 
unchanged after six months (Table 4).
CMR evaluation
Due to the necessity of implanting a cardiac pacemaker (seven 
patients) or an automatic cardioverter-defibrillator (three 
patients) in some of the ASA patients, the CMR evaluation at 
six months could only be carried out in 20 out of 30 subjects 
in this group. On CMR evaluation, the MR volume decreased 
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from 31.9 ± 17 mL before ASA to 22 ± 9.5 mL after the 
procedure (p = 0.045). Using this imaging tool, we observed 
a non-significant LA diameter reduction in the study group at 
month six (from 45.7 ± 8 mm to 43.8 ± 8 mm; p = 0.16). 
The thickness of the basal part of the IVS decreased from 
23.7 ± 2.8 mm to 18.0 ± 4 mm (p < 0.0001), while LW 
thickness decreased from 13.2 ± 3.4 mm to 12.2 ± 2.4 mm 
(p = 0.02) six months after ASA. There was also a significant 
reduction in LV ejection fraction, from 74.2% ± 5.6% to 
71.4% ± 5.6% (p = 0.04) (Table 5).
Table 1. Baseline characteristics of both groups






Age [years] 56.9 ± 11.9 52.1 ± 18.8 0.13
Male sex 15 (50) 8 (40) 0.49
NT-proBNP [pg/mL] 2174.4 ± 819.8 2133.9 ± 1982.8 0.31
NYHA II 3 4
NYHA II/III 8 7
NYHA III 19 9
b-blocker 24 12
Calcium channel blocker 7 5
Amiodarone 3 2
Echocardiographic data:
PG max [mmHg] 122.7 ± 32.8 72.5 ± 29 0.02
EF [%] 71.0 ± 7.6 71.8 ± 8.2 0.36
LA size [mm] 47.4 ± 6.4 49 ± 6.4 0.19
LVEDD [mm] 44.5 ± 5.7 41.7 ± 9.6 0.1
LVEDD [mm] 24.6 ± 4.7 24.3 ± 4.0 0.39
IVSD [mm] 23.6 ± 3.5 24.6 ± 3.2 0.13
LWD [mm] 15.9 ± 3.2 14.8 ± 3 0.09
Mild MR 10 5
Moderate MR 17 15
Significant MR 3 0
Cardiac magnetic resonance data:
EF [%] 74.2 ± 5.6 72.4 ± 7.9 0.6
LV mass [g] 224.6 ± 59.3 198.8 ± 68 0.09
Aorta diameter [mm] 33.4 ± 4.9 33.2 ± 4.6 0.44
LA size [mm] 45.7 ± 8 46.6 ± 8.6 0.89
LVEDD [mm] 42.4 ± 7.4 44.5 ± 7.6 0.32
LVESD [mm] 21.2 ± 4.5 25.1 ± 7.4 0.06
IVSD [mm] 23.7 ± 2.8 24.4 ± 3.9 0.79
LWD [mm] 13.2 ± 3.4 12.5 ± 2.8 0.47
MR volume [mL] 31.9 ± 17 38 ± 13 0.17
Ergospirometric data:
Exercise time [min] 9 ± 4.0 11.3 ± 4.0 0.06
METS 5.1 ± 1.7 6.1 ± 1.1 0.07
VO2/kg 17.4 ± 5.9 21.5 ± 6.9 0.03
% predicted VO2/kg 65 ± 18.2 69.8 ± 17 0.2
Data are shown as number (percentage) or mean ± standard deviation. EF — ejection fraction; IVSD — intraventricular septum diameter; LA — 
left atrium; LV — left ventricle; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic diameter; LWD — lateral  
wall diameter; METS — the metabolic equivalent of task; MR — mitral regurgitation; NT-proBNP — N-terminal pro–B-type natriuretic peptide; 
NYHA — New York Heart Association; PG max — maximal pressure gradient; VO2 — the maximum rate of exercise oxygen consumption
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On CMR examination six months after the procedure, 
an area of late contrast enhancement corresponding to the 
post-ASA scar was observed. Mean infarct size was 14.2 ± 4 g, 
which corresponded to 8.0% ± 4.0% of the total LV mass and 
16.2% ± 4.6% of the IVS mass. 
There was no correlation between the amount of alco-
hol injected, scar size, or CK-MB/TnI level increase, and the 
necessity of pacemaker implantation.
Compared to the initial magnetic resonance image, 
none of the patients had a new area of fibrosis apart from 
the post-ASA scarring. 
LV muscle mass assessment in CMR in patients 
undergoing ASA compared to the OPG
Intraventricular septum mass in ASA patients decreased from 
108.9 ± 20.2 g before the procedure to 91.5 ± 28.9 g at 
six months (p = 0.01), reflecting a 16% mass reduction. The 
decrease of the LV mass at six months was not significant 
(224.6 ± 59.3 g at baseline and 183.8 ± 77.9 g at six months; 
Table 2. Cardiac failure symptoms in both groups, expressed as New York Heart Association (NYHA) class and serum N-terminal 
pro–B-type natriuretic peptide (NT-proBNP) levels at baseline and at six-month follow-up
Study group Pharmacotherapy group
Baseline Six-month follow-up Baseline Six-month follow-up
NT-proBNP [pg/mL] 2174.4 ± 819.8 1103.4 ± 618 2133.9 ± 1982.8 2091.1 ± 1601.2
NYHA I 0 11 0 0
NYHA I/II 0 8 0 0
NYHA II 3 6 4 5
NYHA II/III 8 3 7 8
NYHA III 19 2 9 7
Data are shown as number or mean ± standard deviation.
Figure 1. Serum concentration of N-terminal pro–B-type 
natriuretic peptide (NT-proBNP) [pg/mL] before and six months 
after the alcohol septal ablation (ASA) procedure
Table 3. Echocardiographic data of the study group before and six months after the alcohol septal ablation (ASA) procedure
  Echocardiographic data — study group
Baseline Three months  
after ASA




PG max [mmHg] 122.8 ± 33 51.8 ± 37 37.2 ± 27.8 0.0001
EF [%] 71.0 ± 7.6 70.7 ± 6.6 63.3 ± 8.5 0.04
LA size [mm] 47.4 ± 6.4 45.9 ± 5.1 45.2 ± 5.4 0.06
LVEDD [mm] 44.5 ± 5.7 46.1 ± 4.6 47 ± 5.3 0.05
LVESD [mm] 24.6 ± 4.7 25.3 ± 4 25.5 ± 5.5 0.29
IVSD [mm] 23.6 ± 3.5 19.3 ± 4 19.4 ± 0.4 0.0001
LWD [mm] 15.9 ± 3.2 14.9 ± 2.9 14.2 ± 2 0.007
AWD [mm] 17.6 ± 3.4 15.8 ± 2.4 15.3 ± 2.8 0.06
Mild MR 9 24
Moderate MR 17 4
Significant MR 4 2
Data are shown as number or mean ± standard deviation. AWD — anterior wall diameter; other abbreviations — see Table 1
In the OPG there was no difference between the above 
CMR parameters measured at baseline and at six-month 
follow-up (Table 6).
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–18%; p = 0.18). In the OPG neither the IVS mass nor the 
LV mass changed (Table 6).
The relation between outflow gradient  
reduction and the degree of LV remodelling  
and functional changes
We observed a linear relationship between the LVOT peak 
gradient and LA diameter at six-month follow-up in the study 
group (p = 0.03; r = 0.32; Fig. 2A). A similar relationship was 
found between LVOT peak gradient and NT-proBNP level at 
six months (p = 0.005; r = 0.4; Fig. 2B, nonlinear regression). 
There were no such relationships observed in the OPG.
DISCUSSION
The aim of the study was to confirm whether a successful 
gradient reduction in patients with HOCM improves selected 
parameters related to LV overload. 
We found that successful ASA reduces LVH and serum 
NT-proBNP levels. There was also a trend toward LA size 
reduction, although statistical significance was not achieved.
In patients with HOCM, LA enlargement is a common find-
ing, usually secondary to diastolic LV dysfunction and resultant 
LA overload. Diastolic heart failure often seen in patients with 
HOCM is the reason for elevated end-diastolic LV pressure and 
LV filling pressure, leading to LA enlargement [18]. An additional 
Table 4. Echocardiographic data of the optimal pharmacotherapy group at baseline and after sixth months of optimal  
pharmacotherapy
Echocardiographic data — pharmacotherapy group
Baseline After six months of optimal pharmacotherapy p
PG max [mmHg] 72.5 ± 29 65.3 ± 33 0.44
EF [%] 71.8 ± 8.2 70.8 ± 8.1 0.35
LA size [mm] 49 ± 6.4 49.1 ± 7.9 0.48
LVEDD [mm] 41.7 ± 9.6 44.05 ± 7.0 0.18
LVESD [mm] 24.3 ± 4.0 25.8 ± 8.7 0.25
IVSD [mm] 24.6 ± 3.2 24.8 ± 3.8 0.8
LWD [mm] 14.8 ± 3 14.7 ± 2.8 0.47
Mild MR 5 5
Moderate MR 15 15
Significant MR 0 0
Data are shown as number or mean ± standard deviation. Abbreviations — see Table 1
Table 5. Cardiac magnetic resonance data of the study group before and six months after the alcohol septal ablation (ASA) 
procedure
Cardiac magnetic resonance data — study group
Baseline Six months after ASA P
EF [%] 74.2 ± 5.6 71.4 ± 5.6 0.04
LV mass [g] 224.6 ± 59.3 183.8 ± 77.9 0.18
Aorta diameter [mm] 33.4 ± 4.9 33.8 ± 3.8 0.45
LA size [mm] 45.7 ± 8 43.8 ± 8 0.16
LVEDD [mm] 42.4 ± 7.4 46.3 ± 5.8 0.02
LVESD [mm] 21.2 ± 4.5 27.6 ± 9.5 0.03
IVSD [mm] 23.7 ± 2.8 18.0 ± 4 0.0001
LWD [mm] 13.2 ± 3.4 12.2 ± 2.4 0.02
IVS mass [g] 108.9 ± 20.2 91.5 ± 28.9 0.01
Mass rest [g] 96.2 ± 34.6 92.8 ± 60 0.38
MR volume [mL] 31.9 ± 17 22± 9.5 0.045
Data are shown as mean ± standard deviation. Mass rest — total LV mass minus intraventricular septum (IVS) mass; other abbreviations — see 
Table 1
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detrimental factor increasing LA overload and, in effect, LA size 
is MR observed in patients with HOCM and SAM. In cases of 
significant MR there is additional volume overload of LA lead-
ing to its enlargement [18, 19]. ASA modifies the Venturi effect, 
partly responsible for anterior mitral leaflet movement toward 
the outflow tract, decreasing or even eliminating SAM and MR.
In the group of patients who underwent ASA, a trend 
toward LA size reduction was observed. Additionally, in this 
group we found significant linear relations between the mean 
LA size assessed in TTE and: (1) mean LW thickness evaluated 
by CMR; (2) mean LV mass excluding the IVS assessed by 
CMR; (3) mean LW thickness on TTE measurement.
The above data confirm some earlier observations sug-
gesting that successful ASA leads to partial regression of LVH 
and improves LV diastolic function, thereby decreasing LA 
size [19, 20].
Nagueh et al. [19] investigated LV remodelling and causes 
for LA volume changes in HOCM patients after ASA. The 
authors confirmed that six months after ASA the LA volume 
decreases, and so does the severity of MR. Also, they showed 
a parallel improvement of LV filling parameters. 
Based on CMR measurements, in a group of 52 patients 
at one week and one year after a successful ASA, Yuan et al. 
[21] also observed a significant reduction in LA size.
Figure 2. The relation between left ventricular outflow tract (LVOT) gradient at six months post alcohol septal ablation procedure 
and left atrial size (A), as well as N-terminal pro–B-type natriuretic peptide (NT-proBNP) level (B). In the case of panel B, linear 
regression analysis could not be performed due to non-normal data distribution
Table 6. Cardiac magnetic resonance data of the optimal pharmacotherapy group at baseline and at six-month follow-up
Cardiac magnetic resonance data — pharmacotherapy group
Baseline After six months of optimal pharmacotherapy p
EF [%] 72.4 ± 7.9 72.6 ± 4.7 0.46
LV mass [g] 198.8 ± 68 204.9 ± 56.8 0.39
Aorta diameter [mm] 33.2 ± 4.6 32.3 ± 6.2 0.36
LA size [mm] 46.6 ± 8.6 44.1 ± 7.6 0.25
LVEDD [mm] 44.5 ± 7.6 44.2 ± 4 0.44
LVESD [mm] 25.1 ± 7.4 23.4 ± 4.8 0.28
IVSD [mm] 24.4 ± 3.9 25.6 ± 3.6 0.22
LWD [mm] 12.5 ± 2.8 12.1 ± 2.6 0.37
MR volume [mL] 38 ± 13 36.9 ± 14.7 0.43
Data are shown as mean ± standard deviation. Abbreviations — see Table 1
A B
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In another study assessing the effect of ASA and gradient 
reduction on LA size, the authors used three-dimensional 
(3D) TTE [20]. They performed ASA in a group of 12 patients 
who underwent 3D TTE, in which the end-diastolic and 
end-systolic LA volumes were measured. Consequently, the LA 
ejection fraction (LAEF) was calculated. These measurements 
were done before ASA and three months after. Significant 
LA size reduction and LAEF increase were noted. Moreover, 
the LAEF increase was correlated with LVOT gradient reduc-
tion [20]. Although the primary objective of the paper was 
to validate 3D TTE as a precise modality of LA assessment, 
proving that it is superior to standard TTE in this respect and 
offers similar precision to CMR, the authors also underscored 
the utility of LA volume assessment as a marker of chronic 
diastolic LV dysfunction.
As muscle relaxation during the phase of isovolumetric 
diastole improves, so does the elasticity of the LV during 
diastole. In effect, LV filling pressures decrease, and volumes 
increase, thereby leading to LA size reduction [22]. At the 
same time, reduced degree of MR after ASA decreases LA 
preload, which is an additional mechanism leading to LA size 
reduction [23–25].
Our study supports the view that successful LVOT gradient 
reduction leads to at least some regression of LVH. Further-
more, by improving the diastole and reducing the degree 
of MR, a successful ASA procedure may reduce LA size. An 
interesting observation made in this study is a linear correlation 
of LA size assessed by CMR and NT-proBNP concentration at 
six months after ASA.
Several studies have raised the problem of elevated BNP 
levels in patients with HOCM [9, 10]. This was particularly 
noticeable in patients with HOCM and LVOT obstruction, 
diastolic LV dysfunction, and massive muscle hypertrophy 
[9–11, 26]. 
Impaired relaxation of the LV in HOCM patients has been 
mostly held responsible for muscle wall strain and increased 
BNP synthesis and release [27]. In the investigated group of 
patients after successful ASA, the LVOT gradient decrease and 
LVH regression were accompanied by a significant reduction 
in NT-proBNP levels [27, 28]. 
Based both on published data and the results of this study, 
LVH regression extending also beyond the septal region is 
the most stable marker documenting the improvement of LV 
haemodynamics [28, 29]. It is much more reliable than the 
LVOT gradient itself. The latter varies widely by nature and 
seems an inadequate measure of subaortic outflow obstruc-
tion [30–33]. Possibly, other parameters, easier to assess and 
more stable, may hold a similar value. These may be the LA 
size, which we have failed to satisfactorily demonstrate in this 
study, and, more likely, serum NT-proBNP level reduction. 
According to data presented in this paper, measurement of 
NT-proBNP level should complement the assessment of LVH 
reduction and may also be used as an independent parameter 
of ASA efficacy due to its accessibility.
For a single-centre study the group of enrolled patients 
was limited. This was by necessity a non-randomised study, 
which may be the reason for the insignificant total/lateral wall 
mass reduction on CMR. The number of parameters assessed 
could have been more extensive; we did not assess tissue 
Doppler, 3D echo examination, and strain echo parameters, 
which may have added some more valuable information. 
However, we primarily attempted to assess the value of easily 
accessible parameters reflecting haemodynamic improvement 
in patients after ASA. 
In conclusion, successful ASA leads to partial regression 
of LVH, also beyond the septal region itself, and improves 
LV diastolic function. This is reflected by serum NT-proBNP 
level reduction. Assessing these parameters as part of routine 
follow-up in patients after ASA may help to precisely evaluate 
the efficacy of the procedure, more reliably, perhaps, than 
the measurement of the LVOT gradient alone.
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